Close Menu

urogenital cancer

Out of 13 evaluable patients in the Phase II study, five saw their tumors shrink and four experienced progression-free survival for more than six months.

The diagnostic can now be used to identify a wider range of patients with stage III or metastatic NSCLC who may benefit from first-line treatment with Keytruda.

Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify urothelial carcinoma patients who may benefit from the anti-PD1 immunotherapy.